Viewing Study NCT01083602


Ignite Creation Date: 2025-12-25 @ 4:06 AM
Ignite Modification Date: 2026-02-09 @ 3:17 AM
Study NCT ID: NCT01083602
Status: COMPLETED
Last Update Posted: 2017-12-21
First Post: 2010-03-08
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed and Bortezomib Refractory Multiple Myeloma View
None Refractory Multiple Myeloma View
None Multiple Myeloma in Relapse View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Multiple Myeloma View
None Relapsed Multiple Myeloma View
None Refractory Multiple Myeloma View